EyePoint, Inc. (EYPT)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$4.58+0.22%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
QuarterlyIQ Insights · EYPT
Next print, the company's guidance track record, and the earnings events we've seen in the last few years.
Likelihood the company beats analyst consensus on its next print. Read from its own beat history plus how sector peers have been reporting. Not a price-direction call: a serial beater often has the beat already priced in.
Prints it beat consensus, recent quarters.
Indicative, not a guarantee. Base rate ~71%.
Industry peers that beat since this name last reported.
Management's most recent EPS guidance action.
expected = 0.35*own_median(-9.4) + peer(0.2*0.0) + term(0.0) → -3.28% (capped ±15.0)
Calibrated likelihood the company misses analyst consensus on its next print, read from its own miss history plus its industry base rate. A fundamental tilt, not a price call — and a quiet watch-flag, not an alarm.
Elevated risk of a next-quarter earnings miss: this name is on a run of consecutive earnings misses and operates in a high-miss-rate industry. A fundamental tilt, not a price call.
Calibrated. Base rate ~24%.
Consecutive quarters it missed, most recent run.
How often this industry misses, baseline.
Industry peers that missed in the recent window.
Average absolute move on past earnings days.
Annualized: recent baseline volatility.
Of the last 0 guided quarters.
Actual vs. guided EPS, signed.
Excess return vs. sector ETF, day after print.
Earnings prints and pre-announcements detected in the SEC filing stream.
Results of Operations and Financial Condition. On August 5, 2026, EyePoint, Inc. (the “Company”) issued a press release announcing its financial results for the quarter ended June 30, 2026 and certain other information. A copy of the press release is furnished as Exhibit 99.1 hereto. Also on August 5, 2026, the Company posted an updated investor presentation on its website at www.eyepoint.bio. A copy of the presentation is filed herewith as Exhibit 99.2 and is incorporated by reference herein.
Quarterly EPS and revenue actuals vs. consensus across the last eight quarters (including beat/miss size and the forward consensus heading into the next print) are on the way.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Results of Operations and Financial Condition. On May 6, 2026, EyePoint, Inc. (the “Company”) issued a press release announcing its financial results for the quarter ended March 31, 2026 and certain other information. A copy of the press release is furnished as Exhibit 99.1 hereto.
Results of Operations and Financial Condition. On March 4, 2026, EyePoint, Inc. (the “Company”) issued a press release announcing its financial results for the quarter and year ended December 31, 2025 and certain other information. A copy of the press release is furnished as Exhibit 99.1 hereto.
Results of Operations and Financial Condition. On January 7, 2026, EyePoint, Inc. (the “Company”) issued a press release announcing its preliminary December 31, 2025 cash, and certain other corporate updates. The amounts included in the press release are preliminary, have not been audited and are subject to change upon completion of the Company’s audited financial statements for the year ended December 31, 2025. Additional information and disclosures would be required for a more complete unde…
Results of Operations and Financial Condition. On November 5, 2025, EyePoint Pharmaceuticals, Inc. (the “Company”) issued a press release announcing its financial results for the quarter ended September 30, 2025 and certain other information. A copy of the press release is furnished as Exhibit 99.1 hereto
Results of Operations and Financial Condition. On October 14, 2025, EyePoint Pharmaceuticals, Inc. (the “Company”) posted an updated investor presentation (the “Presentation”) on its website at www.eyepointpharma.com which included estimated cash and investments on hand as of September 30, 2025 and certain other corporate updates. The amounts included in the presentation were calculated prior to the completion of a review by the Company’s independent registered public accounting firm and are…
Results of Operations and Financial Condition. On August 6, 2025, EyePoint Pharmaceuticals, Inc. (the “Company”) issued a press release announcing its financial results for the quarter ended June 30, 2025 and certain other information. A copy of the press release is furnished as Exhibit 99.1 hereto
Results of Operations and Financial Condition. On May 7, 2025, EyePoint Pharmaceuticals, Inc. (the “Company”) issued a press release announcing its financial results for the quarter ended March 31, 2025 and certain other information. A copy of the press release is furnished as Exhibit 99.1 hereto
Results of Operations and Financial Condition. On March 5, 2025, EyePoint Pharmaceuticals, Inc. (the “Company”) issued a press release announcing its financial results for the quarter and year ended December 31, 2024 and certain other information. A copy of the press release is furnished as Exhibit 99.1 hereto.
Results of Operations and Financial Condition. On January 13, 2025, EyePoint Pharmaceuticals, Inc. (the “Company”) posted an updated investor presentation on its website at www.eyepointpharma.com which includes certain financial information as of December 31, 2024. A copy of the presentation is filed herewith as Exhibit 99.1 and is incorporated by reference herein.
Results of Operations and Financial Condition. On November 7, 2024, EyePoint Pharmaceuticals, Inc. (the “Company”) issued a press release announcing its financial results for the quarter ended September 30, 2024 and certain other information. A copy of the press release is furnished as Exhibit 99.1 hereto.
Results of Operations and Financial Condition. On October 28, 2024, EyePoint Pharmaceuticals, Inc. (the “Company”) posted an updated investor presentation (the "Presentation") on its website at www.eyepointpharma.com which included estimated cash and investments on hand as of September 30, 2024 and certain other corporate updates. The amounts included in the presentation were calculated prior to the completion of a review by the Company’s independent registered public accounting firm and are…
Results of Operations and Financial Condition. On August 7, 2024, EyePoint Pharmaceuticals, Inc. (the “Company”) issued a press release announcing its financial results for the quarter ended June 30, 2024 and certain other information. A copy of the press release is furnished as Exhibit 99.1 hereto.
Results of Operations and Financial Condition. On June 26, 2024, EyePoint Pharmaceuticals, Inc. (the “Company”) posted the Company’s 2024 R&D Day Presentation (the “Presentation") on its website at www.eyepointpharma.com , which Presentation included the Company’s estimated cash and investments on hand as of June 30, 2024 and certain other corporate updates. The amounts included in the Presentation were calculated prior to the completion of a review by the Company’s independent registered pub…
Results of Operations and Financial Condition. On May 8, 2024, EyePoint Pharmaceuticals, Inc. (the “Company”) issued a press release announcing its financial results for the quarter ended March 31, 2024 and certain other information. A copy of the press release is furnished as Exhibit 99.1 hereto.
Results of Operations and Financial Condition. On March 7, 2024, EyePoint Pharmaceuticals, Inc. (the “Company”) issued a press release announcing its financial results for the quarter and year ended December 31, 2023 and certain other information. A copy of the press release is furnished as Exhibit 99.1 hereto.